Roche: ‘We will work to eliminate barriers to social media’
September 3, 2010Medical Communications Digital Pharma blog, Roche, social media
Last month Roche broke new ground for pharma by publishing its Social Media Principles (full details of which you can …
Roche set for jobs cuts from 2011
September 3, 2010Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Roche, job cuts
Roche has confirmed it will take wide-ranging steps to reduce costs, following local reports the Swiss pharma firm was poised …
AZ’s Seroquel extends European licence
September 3, 2010Sales and Marketing AstraZeneca, Seroquel
AstraZeneca’s controversial anti-psychotic drug Seroquel has been given the green light in Europe as an add-on treatment for serious depressive …
Merck wins double approval in Europe
September 3, 2010Sales and Marketing Brinavess, Merck & Co, Syncrest, merck sharp and dohme
European regulators have given the green light for two of Merck & Co’s new drugs, licensing its anti-psychotic treatment Sycrest …
Industry supports Australia’s new price deal
September 3, 2010Sales and Marketing Australia, global pricing, price cuts
Australia’s pharmaceutical industry is urging the country’s legislators to pass a new medicines pricing bill that aims to save Aus$1.9 …
UK biotech body elects new chairman
September 3, 2010Research and Development BIA, appointment, research and development
Cellzome’s president and chief executive Tim Edwards has been elected chairman of the BioIndustry Association. Commenting on his election he …
Contract research news in brief
September 3, 2010Research and Development Cyprotex, Epistem, INC Research, Jubilant, Laxal Pharma
A round-up of recent news from the CRO sector, featuring updates from Cyprotex, INC Research, Laxai Pharma, Asuragen, Jubilant Organosys …
Nigel Brooksby joins Prism Ideas
September 2, 2010Medical Communications, Research and Development Prism Ideas, appointment, medical communications, research and development
Former Sanofi-Aventis UK chairman and managing director Nigel Brooksby has joined Cheshire, UK-based Prism Ideas as non-executive chairman. The medical …
Abbott’s Meridia ‘increases heart attack risk’
September 2, 2010Sales and Marketing Abbott, Meridia, drug safety
Abbott’s weight-loss drug Meridia increases the risk of stroke and heart attack in patients with heart disease, according a study …
Genzyme available for ‘fair value’, says Termeer
September 2, 2010Research and Development, Sales and Marketing Genzyme, Sanofi-Aventis
Genzyme’s chief executive Henri Termeer has said his company could be for sale to Sanofi-Aventis if it offers a ‘fair …
Pfizer acquires ‘protein misfolding’ specialist
September 2, 2010Research and Development FoldRx, Pfizer, cystic fibrosis
Pfizer has bolstered its presence in rare and orphan diseases with the acquisition of FoldRx, a US drug discovery firm …
Cephalon chairman takes leave of absence
September 2, 2010Research and Development, Sales and Marketing Cephalon, appointment, research and development, sales and marketing
Cephalon’s chairman and chief executive Frank Baldino Jr is taking a medical leave of absence with immediate effect. The company …
CME Spotlight: Reshaping the healthcare conversation
September 2, 2010Medical Communications CME Spotlight
In a recent conversation with the head of an international group of medical agencies, I was somewhat surprised to hear …
Digital Pharma: Augmented reality gateway for Bayer haemophilia site
September 1, 2010Medical Communications Digital Pharma blog, augmented reality, disease awareness campaigns, haemophilia
Bayer Healthcare has launched a new disease awareness campaign that uses augmented reality techniques to engage with its target audience. …
Lung cancer vaccine poised to begin phase IIb/III trials
September 1, 2010Research and Development NSCLC, TG4010, Transgene, cancer vaccine
French biotech firm Transgene has received positive scientific advice from the EMA for late stage trials of its new lung …
Eye treatment could be commercial breakthrough for ThromboGenics
September 1, 2010Research and Development ThromboGenics, eye care, microplasmin
Belgian biopharma company ThromboGenics could have a major product on its hands in the shape of new eye treatment. The …
EMA to assess GSK flu vaccine for narcolepsy link
September 1, 2010Research and Development, Sales and Marketing GlaxoSmithKline, Pandemrix, h1n1
The European Medicines Agency has launched a review of GlaxoSmithKline’s influenza vaccine Pandemrix. The European Commission asked the EMA to …
Pharma and the iPhone: there’s an app for that
September 1, 2010Medical Communications, Research and Development, Sales and Marketing ipad, iphone
The iPhone and its new, larger cousin the iPad, have captured the hearts of many technology lovers, and have ushered …
Kendle appoints Mark Roseman chief marketing officer
September 1, 2010Research and Development Kendle, appointment, research and development
Mark Roseman has joined clinical research organisation Kendle as senior vice president and chief marketing officer. He has more than …
Talking R&D: Strategic vs full service CRO
September 1, 2010Research and Development CRO, Talking Point, Talking R&D
CRF Health’s Greg Jewett and Medpace’s Alita Hassan debate the merits of a strategic or a full service contract research …
Latest content
Major funding opportunity opens for early cancer diagnostics
Androlabs receives UK authorisation for new Testavan presentation
CEPI backs African-led Bundibugyo Ebola vaccine development
Cytomos appoints life sciences executive to board
